Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm "ASCOT - LLA"

Completed

Phase N/A Results

Results

The trial was stopped early because atorvastatin had resulted in a statistically significant reduction in cardiovascular disease events - stroke (89 vs 121, p = .024), total cardiovascular events (389 vs 486, p=.0005), total coronary events (178 vs 247, p=.0005). Mortality was not statistically signficant (185 vs 212, p=.16).